Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;38(2-3):201-69.
doi: 10.1007/s12016-009-8155-9.

Evidence for the use of intravenous immunoglobulins--a review of the literature

Shaye Kivity  1 , Uriel Katz, Natalie Daniel, Udi Nussinovitch, Neophytos Papageorgiou, Yehuda Shoenfeld
Affiliations
Review

Evidence for the use of intravenous immunoglobulins--a review of the literature

Shaye Kivity et al. Clin Rev Allergy Immunol. 2010 Apr.

Abstract

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature for published data concerning treatment with IVIg. The quality of evidence was assessed, and a summary of the available relevant literature in each disease was given. To our knowledge, this is the first all-inclusive comprehensive review, developed to assist the clinician when considering the use of IVIg in autoimmune diseases, immune deficiencies, and other conditions.

PubMed Disclaimer

References

    1. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gamma globulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36:81–86. - PubMed
    1. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC., Jr ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996–3007. doi: 10.1161/hc4901.102568. - DOI - PubMed
    1. Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus. 2005;14:802–808. doi: 10.1191/0961203303lu2168rr. - DOI - PubMed
    1. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173–184. doi: 10.1385/CRIAI:29:3:173. - DOI - PubMed
    1. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney—a two-edged sword. Semin Arthritis Rheum. 2004;34:593–601. doi: 10.1016/j.semarthrit.2004.06.003. - DOI - PubMed

MeSH terms

Substances